

HOUSE BILL NO. 4607

May 16, 2019, Introduced by Reps. Whitsett, Peterson, Elder, Yancey, Rendon, Hoitenga, Garza, Tate, Chirkun, Cambensy, Haadsma, Kennedy, Brenda Carter, Wozniak, Neeley, Coleman, Jones and Robinson and referred to the Committee on Health Policy.

A bill to amend 1978 PA 368, entitled
"Public health code,"
(MCL 333.1101 to 333.25211) by adding section 16279.

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

1 **Sec. 16279. (1) A licensee who orders a laboratory test for**
2 **the presence of Lyme disease in a human patient shall order an**
3 **enzyme-linked immunosorbent assay test and a western blot assay**
4 **test and shall provide the patient or his or her legal**
5 **representative with written materials on Lyme disease and testing**



1 for Lyme disease before the tests are performed. The written
2 materials must include, but are not limited to, all of the
3 following:

4 (a) Information on each of the following:

5 (i) Available treatment options for Lyme disease.

6 (ii) A list of physicians with expertise in treating Lyme
7 disease.

8 (iii) The symptoms and complications that an individual who is
9 diagnosed with Lyme disease may experience.

10 (b) A notice in substantially the following form:

11 "Your health care provider has ordered a laboratory test for
12 the presence of Lyme disease for you. Current laboratory testing
13 for Lyme disease can be problematic and standard laboratory tests
14 often result in false negative and false positive results. If
15 tested too early, you may not have produced enough antibodies to be
16 considered positive because your immune response requires time to
17 develop antibodies. If you are tested for Lyme disease and the
18 results are negative, this does not necessarily mean that you do
19 not have Lyme disease. If you continue to experience unexplained
20 symptoms, you should contact your health care provider and inquire
21 about the appropriateness of retesting or initial or additional
22 treatment."

23 (2) A licensee who prescribes, administers, or dispenses any
24 of the following for the treatment of Lyme disease in a human
25 patient is not subject to administrative action under sections
26 16221 and 16226:

27 (a) An oral long-term antibiotic.

28 (b) An intravenous antibiotic administered through a vascular
29 access device.



1 Enacting section 1. This amendatory act takes effect 90 days
2 after the date it is enacted into law.

